Jeffrey Winebrenner
Internal Medicine · Chesapeake, VANPI 1184695629
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $939 and has fallen 98.5% since, to $14 in 2024.
Across 92 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$272
- Novo Nordisk$207
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
- Axsome Therapeutics, Inc.$120
- Merck$88
- Daiichi Sankyo Inc.$80
- plus $605 from 17 others
What the payments were for
- Food & beverage$1,557100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $272 |
| Novo Nordisk | 12 | $207 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $185 |
| Axsome Therapeutics, Inc. | 5 | $120 |
| Merck | 5 | $88 |
| Daiichi Sankyo Inc. | 3 | $80 |
| AstraZeneca | 5 | $75 |
| Novartis | 4 | $67 |
| Pfizer | 4 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $61 |
| Lilly USA, LLC | 3 | $48 |
| Astellas Pharma US Inc | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| GSK | 2 | $33 |
| Boehringer Ingelheim | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Bayer | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
How this compares
$1,557 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 20 | $513 |
| Pravastatin Sodium | 14 | $405 |
| Alendronate Sodium | 20 | $374 |
| Levothyroxine Sodium | 29 | $324 |
| Metoprolol Succinate | 16 | $267 |
| Atorvastatin Calcium | 27 | $170 |
| Famotidine | 15 | $115 |
| Metformin Hcl | 12 | $100 |
| Metoprolol Tartrate | 11 | $79 |
| Amlodipine Besylate | 14 | $60 |
| Lisinopril | 12 | $54 |
| Hydrochlorothiazide | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chesapeake
- Luis CarpioChesapeake$13K
- Vernis BeverlyChesapeake$13K
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.